Scroll Top

mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor

mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor

mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor

Abstract
Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the current outlook for mRNA display-based therapeutic development.

Citation

mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor
Sabrina E. Iskandar and Albert A. Bowers
ACS Medicinal Chemistry Letters 2022 13 (9), 1379-1383
DOI: 10.1021/acsmedchemlett.2c00319


This website uses cookies and similar technologies to understand visitor experiences. By using this website, you consent to UNC-Chapel Hill's cookie usage in accordance with their Privacy Notice.
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy.
Required
Tracking
This website uses functions of the web analytics service Google Analytics.
Google Fonts
This site uses so-called web fonts provided by Google for the uniform font representation.
Privacy Policy